Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzamides
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Protein-Tyrosine Kinases
  • Pyrazines

abstract

  • In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).

publication date

  • January 28, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4862586

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1509981

PubMed ID

  • 26641137

Additional Document Info

start page

  • 323

end page

  • 32

volume

  • 374

number

  • 4